Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Global Blood Therapeutics, Inc. (NASDAQ: GBT).

Full DD Report for GBT

You must become a subscriber to view this report.


Recent News from (NASDAQ: GBT)

GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress
SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that data supporting its voxelotor program in sickle cell disease (SCD) will be presented during the 23 rd European Hematology Association (EHA) Congress in Stoc...
Source: GlobeNewswire
Date: May, 17 2018 10:30
Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics
Lucky Seven The Lucky Seven is a swing-trading biotechnology portfolio of seven stocks listed in a way to reflect top picks and risk tolerance. The first three picks are the top picks (in no particular order). Risks are increased the further away a stock sits from #4 (the least risky stoc...
Source: SeekingAlpha
Date: May, 16 2018 03:55
Lucky Seven: Achaogen Likely To Bounce Back
The biotechnology sector ( XBI ) felt good about itself last week. As a result, many of the promising, up-and-coming biotechnology companies saw investors throwing their cash back at them in hopes of profitable returns. We anticipate the trend will continue, at least for a short time: C...
Source: SeekingAlpha
Date: May, 14 2018 08:19
Lucky Seven: Omeros Pops, Exelixis Drops On Phase 3 Flop
Thursday and Friday were eventful days for the Lucky Seven and for biotechnology stocks, in general. It requires portfolio reassessment. First, Some Guidelines Before we begin, I'd like to discuss some additional key points to the purpose of the Lucky Seven portfolio: The goal, for all...
Source: SeekingAlpha
Date: May, 12 2018 00:23
2 Small Biotechs For The Rest Of 2018
"Don't waste your time with explanations: people only hear what they want to hear." - Paulo Coelho Today, we profile two small biotech stocks that are set up to do very well for the rest of 2018. Both seem to be buys at current trading levels either via accumulation or via buy-write order...
Source: SeekingAlpha
Date: May, 11 2018 12:39
Rounds Report: Global Blood Therapeutics Rallied While Improving FDA Policies To Help Nektar
Acquire worldly wisdom and adjust your behavior accordingly. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 09, 2018. As usual, we’ll elucidate notable trading analytics for the day, recent insider transactions, and interesti...
Source: SeekingAlpha
Date: May, 10 2018 02:38
Lucky Seven: Omeros Moves, Array Biopharma May Be Next
iShares Nasdaq Biotechnology ETF ( IBB ) was good for a 0.3% gain within the last three trading days, while the Lucky Seven netted a 2.6% gain. The Lucky Seven portfolio assumes an investor made a $1000 investment, to begin, in each pick. So, the portfolio began with $7,000. Lucky Seven ...
Source: SeekingAlpha
Date: May, 08 2018 15:02
GBT Reports Recent Business Progress and First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the first quarter ended March 31, 2018. "During the first quarter of 2018, we continued to remain f...
Source: GlobeNewswire
Date: May, 07 2018 16:05
Lucky Seven: An Introduction To My Top Biotechnology Picks
Introduction I am a Registered Nurse, currently advancing my education at Purdue University. I work on an intermediate care unit in a hospital where I am responsible for the care and lives of folks who come to me with a myriad of medical conditions. I hope to soon become a nursing professor....
Source: SeekingAlpha
Date: May, 03 2018 05:28
Global Blood Therapeutics: The Anatomy Of A Senseless Drop
Since I presented an investment in Global Blood Therapeutics ( GBT ) as a Grade 'A' opportunity in January, the stock has dropped 20%. In fact, since it rode a cloud after receiving Breakthrough Therapy Designation (BTD) for voxelotor, it has fallen in excess of 30% from its greatest heigh...
Source: SeekingAlpha
Date: April, 30 2018 02:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1748.2548.1048.6547.30647,993
2018-02-2663.6062.5063.8562.10414,889
2018-02-2363.5562.8563.6061.3774538,161
2018-02-2262.3562.6565.0561.50810,032
2018-02-2166.2561.5068.0561.40867,791

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17238,007306,96977.5345Short
2018-08-16279,533580,13448.1842Short
2018-08-1593,283329,19628.3366Cover
2018-08-1457,803242,68723.8179Cover
2018-08-1374,462216,22934.4366Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GBT.


About Global Blood Therapeutics, Inc. (NASDAQ: GBT)

Logo for Global Blood Therapeutics, Inc. (NASDAQ: GBT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $2,287,302,430 - 05/16/2018
  • Issue and Outstanding: 51,825,849 - 04/30/2018

 


Recent Filings from (NASDAQ: GBT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 12 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018

 

 


Daily Technical Chart for (NASDAQ: GBT)

Daily Technical Chart for (NASDAQ: GBT)


Stay tuned for daily updates and more on (NASDAQ: GBT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GBT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GBT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GBT and does not buy, sell, or trade any shares of GBT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/